m-trifluoromethyl-diphenyl diselenide attenuates pentylenetetrazole-induced seizures in mice by inhibiting GABA uptake in cerebral cortex slices

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1127-1133

  Prigol, Marina ^a   Brüning, César A ^a   Godoi, Benhur ^a   Nogueira, Cristina W ^a   Zeni, Gilson ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Brain; Disubstituted diaryl diselenides; GABA; Pentylenetetrazole; Seizures; Uptake

Indexed keywords

2,4 DIAMINOBUTYRIC ACID; 3 TRIFLUOROMETHYLDIPHENYL DISELENIDE; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 CHLORODIPHENYL DISELENIDE; 4 METHOXYLDIPHENYL DISELENIDE; AMINOOXYACETIC ACID; AMINOOXYACETIC ACID HEMIHYDROCHLORIDE; ANTICONVULSIVE AGENT; DIAZEPAM; ORGANOSELENIUM DERIVATIVE; PENTETRAZOLE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; CONVULSION; DRUG MECHANISM; FEMALE; LATENT PERIOD; MOUSE; NONHUMAN; SEIZURE;

EID: 76049104071     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70175-6     Document Type: Article

References (39)

1. Amabeoku GJ: Gamma-aminobutyric acid and glutamic acid receptors may mediate theophylline-induced seizures in mice. Gen Pharmacol, 1999, 32, 365-372.
2. Andersen KE, Braestrup C, Gronwald FC, Jorgensen AS, Nielsen EB, Sonnewald U, Suzdak PD, Knutsen LJS: The synthesis of novel GABA uptake inhibitors. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J Med Chem, 1993, 36, 1716-1725.
3. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T: Progress report on new antiepileptic drugs: A summary of the eigth Eilat Conference. Epilepsy Res, 2007, 73, 1-52.
4. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem, 1976, 72, 248-254.
5. Dolina S, Peeling J, Sutherland G, Pillay N, Greenberg A: Effect of sustained pyridoxine treatment on seizure susceptibility and regional brain amino-acid levels in genetically epilepsy-prone Balb/C mice. Epilepsia, 1993, 34, 33-42.
6. Engelborghs S, D'Hooge R, De Deyn PP: Pathophysiology of epilepsy. Acta Neurol Belg, 2000, 100, 201-213.
7. Gale K: Role of GABA in the genesis of chemoconvulsant seizures. Toxicol Lett, 1992, 64, 417-428.
8. A and 5HT receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, 1508 -1515.
9. Ghisleni G, Porciuncula LO, Cimarostia H, Rocha JBT, Salbego CG, Souza DO: Diphenyl diselenide protects rat hippocampal slices submitted to oxygen-glucose deprivation and diminishes inducible nitric oxide synthase immunocontent. Brain Res, 2003, 986, 196-199.
10. Gram L, Larsson OM, Schousboe A: Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res, 1988, 2, 87-95.
11. Jung ME, Wallis CJ, Gatch MB, Lal H: Sex differences in the pentylenetetrazol-like stimulus induced by ethanol withdrawal. J Pharmacol Exp Ther, 1999, 291, 576-582.
12. Kaplan JP, Raizon BM, Desarmenien M: New anticonvulsants: Schiff bases of γ-aminobutyric acid and γ-aminobutyramide. J Med Chem, 1980, 23, 702-710.
13. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A: GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res, 1987, 1, 77-93.
14. Lippert B, Metcalf BW, Jung MJ, Casara P: 4-Aminohex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem, 1977, 74, 441-445.
15. Loscher W, Honack D, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res, 1991, 8, 71-89.
16. Loscher W, Schmidt D: Strategies in antiepileptic drug development - is rational drug design superior to random screening and structural variation. Epilepsy Res, 1994, 17, 95-134.
17. Machado MS, Rosa RM, Dantas AS, Reolon GK, Appelt HR, Braga AL, Henriques JAN, Roesler R: An organic selenium compound attenuates apomorphine-induced stereotypy in mice. Neurosci Lett, 2006, 410, 198-202.
18. Mattson RH: Efficacy and adverse-effects of established and new antiepileptic drugs. Epilepsia, 1995, 36, S13-S26.
19. Medina AE, Manhaes AC, Schmidt SL: Sex differences in sensitivity to seizures elicited by pentylenetetrazol in mice. Pharmacol Biochem Behav, 2001, 68, 591-596.
20. Meldrum BS: Why and when are seizures bad for de brain? Trends Pharmacol Sci, 2001, 22, 445-446.
21. Morselli PL, Bartholini G, Lloyd KG: Progabide. In: New anticonvulsant drugs. Eds. Meldrum BS, Porter RJ, Libbey, London, 1986, 237-253.
22. Nogueira CW, Zeni G, Rocha JBT: Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev, 2004, 104, 6255-6286.
23. Paulmier C: Selenoorganic functional groups, In: Selenium Reagents and Intermediates in Organic Synthesis, Ed. Paulmier C, 1st ed., Pergamon Press, Oxford, England, 1986, 25-51.
24. Pinto LG, Jesse CR, Nogueira CW, Savegnago L: Evidence for the involvement of glutamatergic and GABAergic systems and protein kinase A pathway in the antinociceptive effect caused by p-methoxy-diphenyl diselenide in mice. Pharmacol Biochem Behav, 2008, 88, 487-496.
25. Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, Kupferberg HJ, Scoville B, White BG: Anti-epileptic drug development program. Cleve Clin Q, 1984, 51, 293-305.
26. Racine RJ: Modification of seizures activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol, 1972, 32, 281-294.
27. Rogawski MA, Porter RJ: Antiepileptic drugs - pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev, 1990, 42, 223-286.
28. Rosa RM, Flores DG, Appelt HR, Braga AL, Henriques JAP, Roesler R: Facilitation of long-term object recognition memory by pretraining administration of diphenyl diselenide in mice. Neurosci Lett, 2003, 341, 217-220.
29. Rowley HL, Martin KF, Marsden CA: Decreased GABA release following tonic-clonic seizures is associated with an increase in extracellular glutamate in rat hippocampus in-vivo. Neuroscience, 1995, 68, 415-422.
30. Savegnago L, Jesse CR, Pinto LG, Rocha JBT, Barancelli DA, Nogueira CW, Zeni G: Diphenyl diselenide exerts antidepressant-like and anxiolytic-like effects in mice: Involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway in its antidepressant-like action. Pharmacol Biochem Behav, 2008, 88, 418-426.
31. Savegnago L, Pinto LG, Jesse CR, Rocha JBT, Nogueira CW, Zeni G: Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, 1261-1269.
32. Schachter SC, Cahill WT, Wannamaker BB, Shu VS, Sommerville KW: Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures. J Epilepsy, 1998, 11, 248-255.
33. Schweigert ID, de Oliveira DL, Scheibel F, da Costa F, Wofchuk ST, Souza DO, Perry MLS: Gestational and postnatal malnutrition affects sensitivity of young rats to picrotoxin and quinolinic acid and uptake of GABA by cortical and hippocampal slices. Develop Brain Res, 2005, 154, 177-185.
34. Sejima H, Ito M, Kishi K, Tsuda H, Shiraishi H: Regional excitatory and inhibitory amino acid concentrations in pentylenetetrazol kindling and kindled rat brain. Brain Dev, 1997, 19, 171-175.
35. Smith MC, Bleck TP: Convulsive disorders: toxicity of anticonvulsants. Clin Neuropharmacol, 1991, 14, 97-115.
36. Sperk GH, Lassmamm H, Baran H, Seitelberger F, Hornykiewicz O: Kainic acid-induced seizures: doserelationship of behavioural, neurochemical and histopathological changes. Brain Res, 1985, 338, 289-295.
37. Swinyard EA, White HS, Wolf HH, Bondinell WE: Anticonvulsant profiles of the potent and orally active GABA uptake inhibitors SK&F 89976-A and SK&F 100330-A and four prototype antiepileptic drugs in mice and rats. Eur J Pharmacol, 1991, 236, 147-149.
38. Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia, 2001, 42, 8-12.
39. Ure JA, Perassolo M: Update on the pathophysiology of the epilepsies. J Neurol Sci, 2000, 177, 1-17.